Gene · 862
Papers4,591
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
501 to 520 of 4,591
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| NETWORK DIFFERENTIAL CONNECTIVITY ANALYSIS. | Ann Appl Stat | 2022 | 37842097 | PubTator, text mining | PubMed |
| C11orf21, a novel RUNX1 target gene, is down-regulated by RUNX1-ETO. | BBA Adv | 2022 | 37082605 | PubTator, text mining | PubMed |
| Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis. | PLOS Glob Public Health | 2022 | 36962909 | PubTator, text mining | PubMed |
| Racial disparities in the genetic landscape of lung cancer. | Cancer Health Disparities | 2022 | 36819657 | PubTator, text mining | PubMed |
| Dysregulated Expression of MiR-19b, MiR-25, MiR-17, WT1, and CEBPA in Patients with Acute Myeloid Leukemia and Association with Graft versus Host Disease after Hematopoietic Stem Cell Transplantation. | South Asian J Cancer | 2022 | 36756106 | PubTator, text mining | PubMed |
| A comprehensive analysis of cytogenetics, molecular profile, and survival among pediatric acute myeloid leukemia: a prospective study from a tertiary referral center. | Am J Blood Res | 2022 | 36742278 | PubTator, text mining | PubMed |
| Chidamide-based 3-drug combination regimen reverses molecular relapse post transplantation in AML1-ETO-positive acute myeloid leukemia. | Front Pharmacol | 2022 | 36712661 | PubTator, text mining | PubMed |
| [Chinese expert consensus of the allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia (not APL) (2022)]. | Zhonghua Xue Ye Xue Za Zhi | 2022 | 36709193 | PubTator, text mining | PubMed |
| [Variables associated with hematological remission and survival in patients with acute myeloid leukemia after induction failure and relapse]. | Zhonghua Xue Ye Xue Za Zhi | 2022 | 36709148 | PubTator, text mining | PubMed |
| [A comparative clinical study of modified IA "3+4" regimen and intermediate-dose cytarabine regimen in the consolidation treatment of low-risk acute myeloid leukemia]. | Zhonghua Xue Ye Xue Za Zhi | 2022 | 36709138 | PubTator, text mining | PubMed |
| Computational approaches for discovering significant microRNAs, microRNA-mRNA regulatory pathways, and therapeutic protein targets in endometrial cancer. | Front Genet | 2022 | 36704357 | PubTator, text mining | PubMed |
| A Rare Case of p190 BCR-ABL B-cell Acute Lymphocytic Leukemia With Excellent Response to Hyper-CVAD and Ponatinib. | Cureus | 2022 | 36699758 | PubTator, text mining | PubMed |
| DeteX: A highly accurate software for detecting SNV and InDel in single and paired NGS data in cancer research. | Front Genet | 2022 | 36685970 | PubTator, text mining | PubMed |
| Acute Promyelocytic Leukemia with Rare Genetic Aberrations: A Report of Three Cases. | Genes (Basel) | 2022 | 36672788 | PubTator, text mining | PubMed |
| A retrospective study on effectiveness of combined recombinant human interferon-α-1b, interleukin-2, and thalidomide for the treatment of acute myeloid leukemia in various disease states. | Ann Transl Med | 2022 | 36660719 | PubTator, text mining | PubMed |
| Sequential Combination of FLAM and Venetoclax plus Azacitidine to Bridge to Cord Blood Transplantation in a Patient with Primary Induction Failure Acute Myeloid Leukemia. | Case Rep Oncol | 2022 | 36636684 | PubTator, text mining | PubMed |
| Mechanism of Datura metel on sinus bradycardia based on network pharmacology and molecular docking. | Medicine (Baltimore) | 2022 | 36626429 | PubTator, text mining | PubMed |
| Krüppel-like Factor 6 Suppresses the Progression of Pancreatic Cancer by Upregulating Activating Transcription Factor 3. | J Clin Med | 2022 | 36615000 | PubTator, text mining | PubMed |
| AML1-ETO-Related Fusion Circular RNAs Contribute to the Proliferation of Leukemia Cells. | Int J Mol Sci | 2022 | 36613512 | PubTator, text mining | PubMed |
| The mechanism study of Miao medicine Tongfengting decoction in the treatment of gout based on network pharmacology and molecular docking. | Medicine (Baltimore) | 2022 | 36595750 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/862/papers?page=26